265 filings
8-K
IMMU
Immunomedics Inc
23 Oct 20
Completion of Acquisition or Disposition of Assets
5:08pm
8-K
IMMU
Immunomedics Inc
21 Sep 20
Other Events
6:00am
8-K
IMMU
Immunomedics Inc
17 Sep 20
Departure of Directors or Certain Officers
4:38pm
8-K
IMMU
Immunomedics Inc
14 Sep 20
Gilead Sciences to Acquire Immunomedics
8:00am
8-K
IMMU
Immunomedics Inc
17 Aug 20
Approval enhances long-term supply of Trodelvy
8:01am
8-K
5rdhfwe
5 Aug 20
Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update
5:00pm
8-K
owb1qsto cszwq49ju
6 Jul 20
The safety profile of Trodelvy was consistent with the FDA-approved label and no new safety signals were observed
8:07am
8-K
h3hru
18 Jun 20
Departure of Directors or Certain Officers
4:16pm
8-K
z7qsxpp2sz0pon fs2x
27 May 20
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
4:08pm
8-K
sz0ih3m3u
7 May 20
Departure of Directors or Certain Officers
7:51am
8-K
tq766pd5b
6 May 20
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update
4:01pm
8-K
5ac14x
1 May 20
Immunomedics Announces Proposed Public Offering of Common Stock
5:13pm
8-K
uc17qz9fh9iq17
22 Apr 20
FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
12:40pm
8-K/A
44r2kb o9qe3dn
20 Apr 20
Departure of Directors or Certain Officers
4:39pm
8-K
8nibdt4 tpkkyv1gdz6
6 Apr 20
Immunomedics Announces Ascent Study to Be Stopped for Compelling Efficacy
8:05am
8-K
4rzndj3pir7jvqvywg
6 Apr 20
Immunomedics Announces Executive Leadership Changes and the Appointment of Harout Semerjian As President and Chief Executive Officer
7:55am
8-K
w92gducc
25 Mar 20
Immunomedics Provides COVID-19 Business Continuity Update, Affirms 2020 Strategic Priorities, and Shares R&D and Regulatory Update
8:02am
8-K
2h2xsfglg6e6rmtz bmh
27 Feb 20
Immunomedics Appoints Robert W. Azelby to Board of Directors
4:20pm
8-K
kt02h77hpaege3evy5tt
27 Feb 20
Immunomedics Reports Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
4:01pm
8-K
s78r1xkb uk0hstxak2
14 Feb 20
Immunomedics Appoints DR. Loretta Itri Chief Medical Officer
8:10am